Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $15.60.

Several equities analysts have recently issued reports on KLRS shares. Morgan Stanley assumed coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price objective for the company. Wedbush assumed coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They set an “outperform” rating and a $17.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Tuesday, June 9th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. Finally, Citizens Jmp decreased their target price on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th.

Insiders Place Their Bets

In other Kalaris Therapeutics news, Director Srinivas Akkaraju bought 244,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $4.83 per share, for a total transaction of $1,179,969.00. Following the completion of the purchase, the director directly owned 2,224,147 shares in the company, valued at $10,742,630.01. This trade represents a 12.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 68.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in KLRS. XTX Topco Ltd acquired a new position in Kalaris Therapeutics during the second quarter worth approximately $65,000. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $58,000. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $130,000. Woodline Partners LP purchased a new stake in shares of Kalaris Therapeutics during the third quarter worth approximately $1,394,000. Finally, WHI TRUST Co LLC acquired a new stake in shares of Kalaris Therapeutics during the fourth quarter worth $823,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

Shares of KLRS opened at $4.27 on Tuesday. The stock has a 50-day simple moving average of $5.32 and a 200-day simple moving average of $7.41. The stock has a market capitalization of $101.58 million, a PE ratio of -1.99 and a beta of 0.15. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06. Analysts predict that Kalaris Therapeutics will post -2.09 EPS for the current year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.